



ADVAXIS, INC. EXPANDED ACCESS & RIGHT TO TRY POLICY FOR INVESTIGATIONAL DRUGS

The Advaxis Management Team and its employees are committed to developing innovative immunotherapies for the treatment of patients with life-threatening diseases and unmet medical needs. Our research and development goal is to create, test, and bring to market new therapies that provide hope and the potential for living longer to patients with advanced cancers and other life-threatening diseases.

We recognize and appreciate the urgent need to advance our investigational therapies through the drug development process in order to gain approval from the U.S. Food and Drug Administration or foreign authorities in order to make them available to the greatest number of patients. This process is rigorous, highly regulated and may be lengthy. Clinical research studies involving a significant number of patients with the same type of disease must be conducted to test the safety and effectiveness of an investigational therapy. Our Advaxis team is focused on completing clinical studies to obtain the definitive safety and efficacy information needed to receive regulatory approval allowing widespread availability of our immunotherapies.

Given the urgent need to make investigational therapies available to patients with devastating diseases, a recognition that not all patients will qualify for enrollment in our clinical studies and a full awareness of the amount of time involved to gain regulatory approval, we have spent a significant amount of time discussing and investigating whether “compassionate use,” “expanded access,” or “right to try” programs would be viable options. We must ensure that we will not cause undue harm to any patient nor compromise the development program by allowing access to an investigational therapy prior to regulatory approval. Based on considerable thought and discussion with our internal team of experts our current company policy is not to allow access to our investigational therapies including AXAL, except through our ongoing clinical studies. However, we will continue to support existing Expanded Access and Compassionate Use agreements including AXAL.

We will strive to achieve our objective of regulatory approval in the most expeditious way possible. In the meantime, we ask each patient to talk to their physician to find out whether there is a clinical study which would meet their needs, allowing access to novel investigational therapies while furthering the development of those products.

To access a list of current company-sponsored clinical trials, please visit www.ClinicalTrials.gov and enter “Advaxis” in the search box. For any questions regarding access to our investigational therapies, please contact Advaxis at: (609) 250-9813 and a member of our team will respond to you within 5 business days.